AstraZeneca has upgraded its annual guidance for the second ... Turnover increased by 21 per cent to $13.6billion in the three months to 30 September. Sales of oncology drugs jumped by 22 per cent to $5.6billion, supported by double-digit percentage ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last projection. The U.S. is AstraZeneca’s largest market, generating 44% of its total revenue, according to its Q3 earnings presentation.

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease pipelines, the company said, with oncology seeing 22% growth. Cardiovascular, renal and metabolism (CVRM) experienced 21% growth, R&I 24% and rare disease 14%.